The basic concept of STING‐agonist‐based combination strategies is to transform the TME from a noninflammatory, immune‐excluded “cold” state to an inflamed, immunostimulatory “hot” state by enhancing the antitumor responses in the cancer‐immune cycle or reducing the evasive effect towards immune defenses.411, 412. This evidence concerns the gene STING1 and cancer.